与老年人哮喘吸入性糖皮质激素治疗反应相关的新遗传变异
该研究在老年哮喘患者中开展全基因组关联研究,探索吸入性糖皮质激素(ICS)治疗反应的药物遗传学。研究在GERA队列5710例受试者中发现并验证了6号染色体上PTCHD4附近的4个新SNP与口服糖皮质激素(OCS) bursts结局在全基因组水平显著相关,另在4541例受试者中验证了152个SNP与哮喘相关急性加重结局相关。
要点
- PTCHD4附近4个新SNP与老年哮喘患者OCS bursts结局在全基因组水平显著相关。
- 152个SNP与哮喘相关急性加重结局相关,涉及GM2A、SNW1等基因。
- 验证的SNP包括CPED1、CRADD、DST等的甲基化和表达数量性状位点。
核心结论
- 在老年哮喘患者中识别出多个与ICS治疗反应相关的新SNP。
- 部分SNP注释到既往与哮喘及其他气道或过敏性疾病相关的基因,包括PTCHD4。
研究设计与样本
- 在GERA队列欧洲裔哮喘患者中开展ICS反应的全基因组关联研究,采用Cox比例风险回归模型。
- 在MGB Biobank和Rotterdam Study中进行验证。
- ICS反应定义:处方记录无OCS bursts,或诊断代码无哮喘相关急性加重。
- 对每个结局进行固定效应荟萃分析。
- 对验证的SNP进行标准数据库功能注释。
主要发现
- GERA队列5710例、MGB Biobank 676例、Rotterdam Study 465例受试者中,6号染色体PTCHD4附近4个新SNP在所有队列中验证,并在荟萃分析中达到全基因组显著性(OCS burst结局)。
- GERA队列4541例和MGB Biobank 505例受试者中,152个SNP(p<5 × 10-5)在两个队列中验证(哮喘相关急性加重结局)。
- 验证的SNP包括OCS burst结局的CPED1、CRADD和DST的甲基化和表达数量性状位点。
- 验证的SNP包括哮喘相关急性加重结局的GM2A、SNW1、CACNA1C、DPH1和RPS10。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Older adults have the greatest burden of asthma and poorest outcomes. The pharmacogenetics of inhaled corticosteroid (ICS) treatment response is not well studied in older adults. METHODS: A genome-wide association study of ICS response was performed in asthmatics of European ancestry in Genetic Epidemiology Research on Adult Health and Aging (GERA) by fitting Cox proportional hazards regression models, followed by validation in the Mass General Brigham (MGB) Biobank and Rotterdam Study. ICS response was measured using two definitions in asthmatics on ICS treatment: (1) absence of oral corticosteroid (OCS) bursts using prescription records and (2) absence of asthma-related exacerbations using diagnosis codes. A fixed-effect meta-analysis was performed for each outcome. The validated single-nucleotide polymorphisms (SNPs) were functionally annotated to standard databases. RESULTS: In 5710 subjects in GERA, 676 subjects in MGB Biobank, and 465 subjects in the Rotterdam Study, four novel SNPs on chromosome six near PTCHD4 validated across all cohorts and met genome-wide significance on meta-analysis for the OCS burst outcome. In 4541 subjects in GERA and 505 subjects in MGB Biobank, 152 SNPs with p<5 × 10-5 were validated across these two cohorts for the asthma-related exacerbation outcome. The validated SNPs included methylation and expression quantitative trait loci for CPED1, CRADD and DST for the OCS burst outcome and GM2A, SNW1, CACNA1C, DPH1, and RPS10 for the asthma-related exacerbation outcome. CONCLUSIONS: Multiple novel SNPs associated with ICS response were identified in older adult asthmatics. Several SNPs annotated to genes previously associated with asthma and other airway or allergic diseases, including PTCHD4.
引用
- Wang AL, Lahousse L, Dahlin A, et al. Novel genetic variants associated with inhaled corticosteroid treatment response in older adults with asthma. Thorax. 2022. PMID: 35501119. doi:10.1136/thoraxjnl-2021-217674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。